AMGN · Full Picture

AMGEN INC — the full picture

Earnings window · 2026-07-15 to 2026-09-24 · anchored on the 10-Q report

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Revenue Performance and Mix · Revenue growth & mixPriority 89
    +1.5% revenue; 3 sources (news, press_release, sec_filing); 4 forward row(s); structured_verified
    UPLIZNA sales increased 90% year-over-year to $335 million in the second quarter, primarily driven by volume growth.
  2. Guidance and Outlook · Guidance & outlookPriority 85
    +0.6% revenue; 3 sources (news, press_release, sec_filing); 16 forward row(s); quote_verified
    Amgen raised full-year 2026 guidance to total revenue between US$38.20 billion and US$39.40 billion.
  3. Operating Cash Flow Trends · Cash flow generationPriority 81
    +17.6% cash (realized); 3 sources (news, press_release, sec_filing); structured_verified
    Operating cash flow was $4.0 billion in Q2 ’26 versus $2.3 billion in Q2 ’25, an increase of $1.7 billion.
  4. Operating Expense Trends · Operating expenses (SG&A)Priority 72
    -125.1% operating_income; 2 sources (press_release, sec_filing); 2 forward row(s); structured_verified
    Total estimated future amortization of finite-lived intangible assets remaining: six months ending Dec 31, 2026 $1.8 billion; 2027 $3.6 billion; 2028 $2.8 billion; 2029 $2.3 billion; 2030 $2.2 billion; 2031 $2.1 billion
  5. Operating Income and Margins · Operating income & profitabilityPriority 69
    +31.9% operating_income (realized); 2 sources (press_release, sec_filing); quote_verified
    For the second quarter, GAAP operating income increased from $2.7 billion to $3.5 billion.
  6. Liquidity and Debt Position · Debt, leverage & refinancingPriority 63
    -9.5% liability (realized); 1 forward row(s); structured_verified
    During the six months ended June 30, 2026, we repaid the €750 million aggregate principal amount of our 2.00% 2026 euro Notes ($833 million upon settlement of the related cross-currency swap), compared to $3.5 billion of debt repayments during the six months ended June 30, 2025.
  7. Quarterly Dividend Declaration · Buybacks & dividendsPriority 63
    2 sources (news, sec_filing); 2 forward row(s); quote_verified
    Declared quarterly dividend: $2.52 per share.
  8. Competition and Pricing Pressure · Competition & market sharePriority 62
    -3.8% revenue (realized); 3 sources (news, press_release, sec_filing); quote_verified
    Prolia sales decreased 32% year-over-year to $759 million in the second quarter, driven by 20% lower volume and 12% lower net selling price as multiple biosimilars have launched globally with more biosimilars expected.
  9. Capital Expenditure Outlook · UnclassifiedPriority 55
    2 forward row(s); quote_verified
    For the full year 2026, capital expenditures are expected to be approximately $2.6 billion.
  10. Capital Expenditures Program · Capital expenditurePriority 55
    -2.3% cash; 2 sources (press_release, sec_filing); 2 forward row(s); structured_verified
    Cash used in investing activities during the six months ended June 30, 2026 and 2025 was primarily due to capital expenditures of $1.2 billion and $780 million, respectively, including construction costs for new plants and expansion of manufacturing capacity.
  11. Capital Return Program · Buybacks & dividendsPriority 53
    1 forward row(s); quote_verified
    For the full year 2026, share repurchases are not to exceed $3.0 billion.
  12. Regulatory Approval Milestones · Regulatory action & investigationsPriority 53
    3 sources (news, press_release, sec_filing); 4 forward row(s); quote_verified
    On April 27, 2026 CDER issued a proposal to withdraw approval of TAVNEOS and on April 30, 2026 FDA posted a notice proposing to withdraw approval and announced an opportunity to request a hearing

Threads by pillar

Revenue & Demand Priority 95 · 6 threads

Costs & Margins Priority 81 · 5 threads

Capital & Balance Sheet Priority 92 · 7 threads

Strategy & Portfolio Priority 56 · 4 threads

Legal, Regulatory & Policy Priority 76 · 11 threads

Guidance & Outlook Priority 85 · 1 thread

Macro & Market Conditions Priority 65 · 3 threads

Management & Governance Priority 30 · 1 thread

Unclassified Priority 75 · 5 threads

Expected impact by metric

metricforward netforward grossrealized
operating_income-125.1%+125.1%+44.9%
liability-2.2%+2.5%-9.5%
cash-2.3%+2.3%+20.3%
assets+2.3%+2.3%+6.5%
revenue+2.0%+2.0%+36.5%
net_income-0.6%+0.6%+10.3%
margin——+20.4%